Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : FDA approved its investigational new drug application for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinson’s diseas...
Product Name : MSCTC-0010
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 08, 2020
Reset All
